Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Asset Writedowns and Impairment (2018 - 2025)

Bio-Techne has reported Asset Writedowns and Impairment over the past 5 years, most recently at $84.2 million for Q2 2025.

  • Quarterly results put Asset Writedowns and Impairment at $84.2 million for Q2 2025, up 428.46% from a year ago — trailing twelve months through Jun 2025 was $96.4 million (up 505.51% YoY), and the annual figure for FY2025 was $80.5 million, up 266.54%.
  • Asset Writedowns and Impairment for Q2 2025 was $84.2 million at Bio-Techne, up from -$3.7 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for TECH hit a ceiling of $84.2 million in Q2 2025 and a floor of -$3.7 million in Q1 2025.
  • Median Asset Writedowns and Impairment over the past 3 years was $15.9 million (2024), compared with a mean of $23.1 million.
  • Peak annual rise in Asset Writedowns and Impairment hit 428.46% in 2025, while the deepest fall reached 428.46% in 2025.
  • Bio-Techne's Asset Writedowns and Impairment stood at $18.7 million in 2021, then fell by 14.91% to $15.9 million in 2024, then skyrocketed by 428.46% to $84.2 million in 2025.
  • The last three reported values for Asset Writedowns and Impairment were $84.2 million (Q2 2025), -$3.7 million (Q1 2025), and $15.9 million (Q2 2024) per Business Quant data.